Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Open-Label, Phase Ia/Ib Clinical Study of NW-301V in Advanced Solid Tumors Harboring KRAS G12V Mutations

NCT07875920 is registered in ClinicalTrials.gov with Neowise Biotechnology as lead sponsor.

NCT NCT07875920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07875920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Open-Label, Phase Ia/Ib Clinical Study of NW-301V in Advanced Solid Tumors Harboring KRAS G12V Mutations
Lead sponsor
Neowise Biotechnology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2033
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, colorectal adenocarcinoma, colorectal cancer, kras g12v, lung adenocarcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma (pdac)